Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Windtree Therapeutics ( (WINT) ) has shared an update.
On January 5, 2026, Windtree Therapeutics, Inc. announced that Eric L. Curtis resigned from his roles as President and Chief Operating Officer, effective immediately. The abrupt leadership change may signal a period of transition for the company’s executive team and could prompt investors and other stakeholders to reassess management stability and future strategic direction.
The most recent analyst rating on (WINT) stock is a Hold with a $0.03 price target. To see the full list of analyst forecasts on Windtree Therapeutics stock, see the WINT Stock Forecast page.
Spark’s Take on WINT Stock
According to Spark, TipRanks’ AI Analyst, WINT is a Neutral.
The score is driven primarily by very weak financial performance (minimal revenue, large ongoing losses, heavy cash burn, and negative equity increasing financing risk) and a strongly bearish technical setup (price below key moving averages with negative momentum). Valuation provides little support given negative earnings and no dividend yield data.
To see Spark’s full report on WINT stock, click here.
More about Windtree Therapeutics
Average Trading Volume: 293,520
Technical Sentiment Signal: Sell
Current Market Cap: $1.11M
For a thorough assessment of WINT stock, go to TipRanks’ Stock Analysis page.